Skip to main content
Clinical Trials/NCT04088422
NCT04088422
Recruiting
Not Applicable

Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management

Ruijin Hospital1 site in 1 country320 target enrollmentSeptember 28, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mature B-Cell Lymphoma
Sponsor
Ruijin Hospital
Enrollment
320
Locations
1
Primary Endpoint
progression free survival
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.

Registry
clinicaltrials.gov
Start Date
September 28, 2022
End Date
December 2026
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zhao Weili

Professor

Ruijin Hospital

Eligibility Criteria

Inclusion Criteria

  • Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
  • 18 years or older

Exclusion Criteria

  • Chemotherapy before
  • Other tumors

Outcomes

Primary Outcomes

progression free survival

Time Frame: 2-year

Secondary Outcomes

  • overall survival(2-year)
  • Complete Response rate(6 weeks after treatment)

Study Sites (1)

Loading locations...

Similar Trials